Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/05/18
End: 03/31/22
Due: 03/31/23
Phase: N/A
Priority: Normal
Start: 09/01/23
End: 12/01/25
Due: 12/01/26
Phase: N/A
Priority: Normal
Start: 07/01/23
End: 12/30/24
Due: 12/30/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | NCT03355859 | Zhao Weili | user2@example.com | None | 2018-01-05 | 2022-03-31 | 2023-03-31 | - | - | 2025-07-14 |
| Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | NCT05979792 | Zhao Weili | user2@example.com | None | 2023-09-01 | 2025-12-01 | 2026-12-01 | - | - | 2025-07-14 |
| A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | NCT05883709 | Zhao Weili | user2@example.com | None | 2023-07-01 | 2024-12-30 | 2025-12-30 | - | - | 2025-07-14 |